|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Clinical application of hepatocyte transplantation: current status, applicability, limitations and future outlook.
Minh Phuong Nguyen, Vandana Jain, Valeria Iansante, Ragai R. Mitry, Celine Filippi & Anil Dhawan
Received 20 Dec 2019, Accepted 20 Feb 2020, Accepted author version posted online: 26 Feb 2020
Download citation https://doi.org/10.1080/17474124.2020.1733975 CrossMark Logo CrossMark
Accepted author version
Introduction
Hepatocyte transplantation (HT) is a promising alternative to liver transplantation for treatment of liver-based metabolic diseases and acute liver failure (ALF). However, shortage of good-quality liver tissues, early cell loss post-infusion, reduced cell engraftment and function restricts clinical application.Areas covered: A comprehensive literature search was performed to cover pre-clinical and clinical HT studies. The review discusses the latest developments to address HT limitations: cell sources from marginal/suboptimal donors to neonatal livers, differentiating pluripotent stem cells into hepatocyte-like cells, in vitro expansion, prevention of immune response to transplanted cells by encapsulation or using innate immunity-inhibiting agents, and enhancing engraftment through partial hepatectomy or irradiation.Expert Opinion: To date, published data are highly encouraging specially the alginate-encapsulated hepatocyte treatment of children with ALF. Hepatocyte functions can be further improved through co-culturing with mesenchymal stromal cells. Moreover, ex-vivo genetic correction will enable the use of autologous cells in future personalized medicine.
Keywords: Hepatocyte transplantation, mature hepatocytes, neonatal hepatocytes, mesenchymal stromal cells, encapsulation, engraftment, cryopreservation, alpha-1 antitrypsin, in vitro expansion, partial hepatectomy, irradiation
Disclaimer
As a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also.
Additional information
Funding
This paper has not been funded.
Article Highlights
Hepatocyte transplantation is a highly promising alternative to whole liver transplantation with excellent therapeutic benefit for patients suffering from numerous liver diseases
One of the major limitations of hepatocyte transplantation is up to 70% massive early cell loss after infusion but a recent study suggests that alpha-1 antitrypsin can significantly reduce immune response responsible for that by inhibiting the coagulation and complement pathways
Neonatal-derived hepatocytes have been shown to be superior to adult mature hepatocytes with higher cell viability and yield on isolation and overall better recovery post-thawing with greater maintained hepatic functions
Engraftment of transplanted hepatocytes can be improved through selective and highly proliferative stimulus following partial hepatectomy
Current strategies to advance transplantation of hepatocytes include large-scale production of cells through in vitro expansion, differentiation of pluripotent stem cells into hepatic lineages and cell encapsulation
Primary hepatocytes can be alginate-embedded and have proved great efficacy in providing treatment to patients with lived-based metabolic disorders, ‘bridge’ to liver transplantation and temporary therapy while native liver can regenerate thus discarding the need for whole organ replacement
Human hepatocyte microbeads have demonstrated high safety and efficacy in children with acute liver failure
The source of cells for transplantation is starting to come from patients themselves where successful correction and infusion of autologous cells won’t trigger any immune rejection |
|
发表于 2020-2-28 12:45